المؤلفون: van der Wekken AJ; Department of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands., Kuiper JL; Department of Pulmonary Diseases, VU University Medical Centre, Amsterdam, Netherlands., Saber A; Department of Pathology and Medical Biology, Groningen, University of Groningen, Groningen, Netherlands., Terpstra MM; University of Groningen, Department of Genetics, Groningen, Netherlands., Wei J; University of Groningen, Department of Genetics, Groningen, Netherlands., Hiltermann TJN; Department of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands., Thunnissen E; Department of Pathology, VU University Medical Centre, Amsterdam, Netherlands., Heideman DAM; Department of Pathology, VU University Medical Centre, Amsterdam, Netherlands., Timens W; Department of Pathology and Medical Biology, Groningen, University of Groningen, Groningen, Netherlands., Schuuring E; Department of Pathology and Medical Biology, Groningen, University of Groningen, Groningen, Netherlands., Kok K; University of Groningen, Department of Genetics, Groningen, Netherlands., Smit EF; Department of Pulmonary Diseases, VU University Medical Centre, Amsterdam, Netherlands.; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., van den Berg A; Department of Pathology and Medical Biology, Groningen, University of Groningen, Groningen, Netherlands., Groen HJM; Department of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands.

المصدر: PloS one [PLoS One] 2017 Aug 30; Vol. 12 (8), pp. e0182885. Date of Electronic Publication: 2017 Aug 30 (Print Publication: 2017).

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

مواضيع طبية MeSH: Gene Expression Regulation, Neoplastic*, Antineoplastic Agents/*therapeutic use , Carcinoma, Non-Small-Cell Lung/*mortality , Drug Resistance, Neoplasm/*genetics , ErbB Receptors/*genetics , Lung Neoplasms/*mortality , Quinazolines/*therapeutic use, ADAMTS Proteins/genetics ; ADAMTS Proteins/metabolism ; Adult ; Afatinib ; Aged ; Aged, 80 and over ; Calcium-Binding Proteins/genetics ; Calcium-Binding Proteins/metabolism ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Disease Progression ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/metabolism ; Erlotinib Hydrochloride/therapeutic use ; Exome ; Female ; Gefitinib ; Genome-Wide Association Study ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Male ; Microfilament Proteins/genetics ; Microfilament Proteins/metabolism ; Middle Aged ; Mutation ; Phosphatidylinositol 3-Kinases/genetics ; Phosphatidylinositol 3-Kinases/metabolism ; Protein Kinase Inhibitors/therapeutic use ; Signal Transduction ; Tumor Suppressor Protein p53/genetics ; Tumor Suppressor Protein p53/metabolism ; Wnt Proteins/genetics ; Wnt Proteins/metabolism ; Calponins

المؤلفون: van der Wekken AJ; Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Netherlands. Electronic address: a.j.van.der.wekken@umcg.nl., Saber A; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Netherlands., Hiltermann TJ; Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Netherlands., Kok K; Department of Genetics, University of Groningen, University Medical Center Groningen, Netherlands., van den Berg A; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Netherlands., Groen HJ; Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Netherlands.

المصدر: Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2016 Apr; Vol. 100, pp. 107-16. Date of Electronic Publication: 2016 Jan 25.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Elsevier Scientific Publishers Country of Publication: Netherlands NLM ID: 8916049 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0461 (Electronic) Linking ISSN: 10408428 NLM ISO Abbreviation: Crit Rev Oncol Hematol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung/*drug therapy , Drug Resistance, Neoplasm/*genetics , Lung Neoplasms/*drug therapy , Protein Kinase Inhibitors/*therapeutic use , Pyrazoles/*therapeutic use , Pyridines/*therapeutic use , Quinazolines/*therapeutic use, Afatinib ; Animals ; Carcinoma, Non-Small-Cell Lung/genetics ; Crizotinib ; Epithelial-Mesenchymal Transition/drug effects ; Epithelial-Mesenchymal Transition/genetics ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/genetics ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Lung Neoplasms/genetics ; Receptor Protein-Tyrosine Kinases/antagonists & inhibitors

المؤلفون: Aerts JG; Department of Pulmonary Diseases, Amphia Hospital, Breda., Codrington H, Lankheet NA, Burgers S, Biesma B, Dingemans AM, Vincent AD, Dalesio O, Groen HJ, Smit EF

مؤلفون مشاركون: NVALT Study Group

المصدر: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2013 Nov; Vol. 24 (11), pp. 2860-5. Date of Electronic Publication: 2013 Aug 28.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Carcinoma, Non-Small-Cell Lung/*drug therapy , Carcinoma, Non-Small-Cell Lung/*pathology , Quinazolines/*administration & dosage, Adult ; Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/mortality ; Disease-Free Survival ; Docetaxel ; Erlotinib Hydrochloride ; Female ; Glutamates/administration & dosage ; Guanine/administration & dosage ; Guanine/analogs & derivatives ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Pemetrexed ; Recurrence ; Taxoids/administration & dosage

المؤلفون: Groen HJ; Department of Pulmonary Diseases, University Medical Center Groningen, Groningen, The Netherlands. h.j.m.groen@long.umcg.nl, Socinski MA, Grossi F, Juhasz E, Gridelli C, Baas P, Butts CA, Chmielowska E, Usari T, Selaru P, Harmon C, Williams JA, Gao F, Tye L, Chao RC, Blumenschein GR Jr

المصدر: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2013 Sep; Vol. 24 (9), pp. 2382-9. Date of Electronic Publication: 2013 Jun 20.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Carcinoma, Non-Small-Cell Lung/*drug therapy , Indoles/*therapeutic use , Lung Neoplasms/*drug therapy , Pyrroles/*therapeutic use , Quinazolines/*therapeutic use, Adult ; Aged ; Angiogenesis Inhibitors/adverse effects ; Angiogenesis Inhibitors/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Non-Small-Cell Lung/mortality ; Disease-Free Survival ; Double-Blind Method ; ErbB Receptors/antagonists & inhibitors ; Erlotinib Hydrochloride ; Female ; Humans ; Indoles/adverse effects ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/therapeutic use ; Pyrroles/adverse effects ; Quinazolines/adverse effects ; Receptors, Platelet-Derived Growth Factor/antagonists & inhibitors ; Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors ; Sunitinib ; Survival ; Treatment Outcome

المؤلفون: Kuiper JL; Department of Pulmonary Diseases, VU University Medical Center, P.O. Box 7057, Amsterdam 1007 MB, The Netherlands., Lind JS, Groen HJ, Roder J, Grigorieva J, Roder H, Dingemans AM, Smit EF

المصدر: British journal of cancer [Br J Cancer] 2012 Nov 20; Vol. 107 (11), pp. 1820-5. Date of Electronic Publication: 2012 Oct 18.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study

بيانات الدورية: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Carcinoma, Non-Small-Cell Lung/*drug therapy , ErbB Receptors/*antagonists & inhibitors , Lung Neoplasms/*drug therapy , Niacinamide/*analogs & derivatives , Phenylurea Compounds/*administration & dosage , Protein Kinase Inhibitors/*administration & dosage , Quinazolines/*administration & dosage , Receptors, Vascular Endothelial Growth Factor/*antagonists & inhibitors, Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Disease-Free Survival ; Erlotinib Hydrochloride ; Female ; Humans ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Neoplasm Staging ; Niacinamide/administration & dosage ; Prognosis ; Sorafenib